
CIEA NOG Mouse®
408
NOD.Cg-PrkdcscidIl2rgtm1Sug/JicCrl
【CIEM正式授权】异种细胞/组织移植、人源化免疫系统重建、肿瘤免疫治疗、传染病研究、GvHD模型等
品系来源
NOG小鼠由日本实验动物研究所(CIEM)的Mamoru Ito培育而成。Ito博士领导的小组在CIEM通过杂交NOD/scid小鼠和γ-链IL-2受体(一些细胞因子的受体)敲除(IL2rγKO)小鼠成功建立了一个免疫功能严重不全的小鼠品系,称之为NOG(NOD/Shi-scid IL-2R小鼠品系)小鼠。与NOD/scid小鼠相比,NOG小鼠的人体细胞和组织移植存活率显著提高,同时能够植入更高比例的正常或癌变人类细胞和组织。
【维通利华 - 中国大陆地区CIEM官方授权经销商 - NOG模型系列】
✈ 2014年维通利华从CIEM引入该品系核心群,2019年维通利华对该品系进行了clone back,2024年重新引入核心群。
应用特性
毛色:白化
研究用途:
- 异种移植:人源组织/器官移植、CDX/PDX模型制备
- 人源化免疫系统重建:huPBMC-NOG、huHSC-NOG
- 肿瘤免疫治疗:双特异性抗体,免疫检查点抑制剂,免疫调节药物+其他药物组合疗法
- CAR-T/CAR-NK等细胞治疗
- 传染病研究
- GVHD模型
- 人类细胞药物的安全性评价
- 造血机制及干细胞基础研究
特性:
- NOD背景,携带SCID突变,IL-2受体γ链基因突变
- NOD背景导致小鼠NK细胞功能低下,补体和巨噬细胞活性降低,且NOD背景小鼠巨噬细胞表面的信号调节蛋白sirpα,对人CD47具有高亲和力,利于人类细胞/组织的移植
- SCID突变系导致T和B淋巴细胞功能缺失
- IL-2受体γ链基因突变引起NK细胞和DCs功能缺陷(即IFN-γ)
- 具备无渗透率的优势 寿命长,可达1.5年
- 自发性淋巴瘤发生率非常低(Kato C, et al., 2009)
- 对辐射较敏感,人源造血干细胞CD34+移植,X射线的辐射剂量不要超过2.0Gy
NOG与NOD SCID、BALB/c小鼠的T、B、NK细胞比例
小鼠均为5周龄雌性。
价格规格
品系代码 | 品系名称 | 日/周龄 | 性别 | VAF/SPF级 | Elite/SPF级 |
408 |
NOG
|
1-5周
|
雄/雌
|
435 | |
408 |
NOG
|
6-8周
|
雄/雌
|
450 | |
408 |
NOG
|
9-10周
|
雄/雌
|
465 |
*以上规格与价格自2025年1月1日至2025年12月31日有效。
生长曲线
CIEA NOG Mouse®
附录资料
- 血液学与血生化-NOG-2023
- General characteristics of NOG mice
- Establishment of patient-derived cancer xenografts in immunodeficient NOG mice
- Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models
- Spontaneous thymic lymphomas in the non-obese diabetic/Shi-scid, IL-2Rγnull mouse
- Incidence of spontaneous lymphomas in non-experimental NOG mice
应用文献
NOG Publications
Authors |
Year |
Paper Title |
Keywords |
Stecklum, Maria, et al. |
2024 |
Humanization of NOG mice and next generation NOG mouse strains |
Humanized mice,CD34+HSC, CDX, PDX, checkpoint inhibitor |
TakashiTamura, et al. |
2024 |
extrapolability; tumorigenicity test; syngeneic transplantation; allogeneic transplantation; NOG mouse; induced pluripotent stem cell. |
|
Tongcheng Dai, et al. |
2024 |
Lymphocyte-activation gene 3 (LAG-3), T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT), Bispecific monoclonal antibody, Immune checkpoint inhibitor, Cancer immunotherapy |
|
Norihiro Tsuneyoshi, et al. |
2024 |
Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity |
Human iPSC, Gene engineering, Hypoimmunogenic pluripotent cells, HLA-G, PD-L1, PD-L2, Suicide gene |
Wentong Jia, et al. |
2024 |
recurrent pregnancy loss, CD56+CD39+ dNK subset, NOG mice, adoptive transfer, placental trophoblast cell fate, M-CSF |
|
Xuetong Wang, et al. |
2024 |
A splicing isoform of PD-1 promotes tumor progression as a potential immune checkpoint |
CD8-positive T cells, T cells, Cancer immunotherapy, Alternative splicing |
Carina Metz, et al. |
2024 |
Orf virus, poxvirus, viral vector, vaccine, environmental risk assessment, biodistribution, shedding |
|
Dan Wang, et al. |
2024 |
allogeneic CD19‐CAR‐DNTs, B‐cell malignancies, cytotoxicity and safety, off‐the‐shelf immunotherapy |
|
Tian Deng, et al. |
2024 |
Rapidly-manufactured CD276 CAR-T cells exhibit enhanced persistence and efcacy |
CD276, Chimeric antigen receptor, Rapidly-manufactured CAR-T, Dash CAR-T, Pancreatic cancer |
Qinghui Xiong, et al. |
2024 |
The development of chimeric antigen receptor T-cells against CD70 for renal cell |
CD70, Chimeric Antigen Receptor T-Cells, Renal Cell Carcinoma, Nanobody |
Klaus-Peter Künkele, et al. |
2023 |
Vγ9Vδ2 T cell; chimeric antigen receptor(CAR); carcinoembryonic antigen(CEA); graft-versus-host disease(GVHD); off-the-shelf; glucocorticoid-induced TNFR-related protein(GITR); tetrakis-pivaloyloxymethyl 2-(thiazole-2-ylamino)ethylidene-1,1-bisphosphonate(PTA) |
|
S. Momsen Reincke |
2023 |
Chimeric autoantibody receptor T cells deplete |
(NMDAR-CAAR) T cells, B cell, Naml6 |
Kevin H Lin, et al. |
2023 |
AML, P2RY2-AKT, XPO1 |
|
Jie Wang et al. |
2022 |
Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies |
CD79b, bispecific, T cell engager, non-hodgkin lymphoma, immunotherapy |
Takeda, Maki et al. |
2021 |
human induced pluripotent stem cells; Irradiation; Stem cell therapy; Tumorigenicity. |
|
M. Ito, et al. |
2008 |
B cell, IgG antibody, HSC, humanized |
|
Yujeong Her, et al. |
2022 |
Development of humanized patient-derived xenograft models for triple negative breast cancer |
|
Yili Chen, et al. |
2021 |
A bispecific antibody targeting HER2 and PD-L1 inhibits |
HER2/PD-L1, BsAbs, ductal carcinoma, gastric carcinoma, PBMCs, humanized |
Shoichi Iriguchi, et al. |
2020 |
CAR-T, iPSC-derived T cell, |
|
Tea Soon Park, et al. |
2020 |
Naïve diabetic vascular progenitors (N-DVP), hiPSC, |
|
Daisuke Doi, et al. |
2020 |
dopaminergic progenitors (DAPs) , iPSC-derived, Parkinson's disease, safety and efficacy assessment |
|
Michael J. Giffin, et al. |
2021 |
BiTE, SCLC, DLL3, PDX, PBMCs, humanized |
|
(VR)Guojuan Miao, et al. |
2021 |
Development of a novel anti-B7-H4 antibody enhances anti-tumor immune response of human T cells |
B7-H4, antibody, pan T cell, humanized, combined therapy |
Hirotoshi Akane, et al. |
2021 |
Spontaneous granulocytic leukemia in a NOD/Shi-scid IL-2Rγnull mouse |
granulocytic leukemia, spontaneous tumor |
Chie Kato, et al. |
2009 |
Spontaneous thymic lymphomas in the non-obese diabetic/Shi-scid, IL-2Rgnull mouse |
spontaneous thymic lymphoma, T cell |
Yang Gao, et al. |
2021 |
intrahepatic cholangiocarcinoma, PDX, lenvatinib |
|
Yuji Yamashita, et al. |
2021 |
Data on long-term survival of the NOD/Shi-scid IL-2Rγ null (NOG) mouse in two facilities |
survival rate, histopathology, tumorigenicity |
Shahrokh Abdolahi, et al. |
2021 |
Adaptive NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric Cancer Model |
NK cell therapy, anti-PD-1 antibody, gastric cancer |
Yoichi Shida, et al. |
2021 |
NK cell therapy, PD-1/PD-L1, glioblastoma |
|
N Ahmadbeigi, et al. |
2021 |
Characterization of a xenograft model for anti-CD19 CAR T cell studies |
CAR-T cells, Raji cells, lymphoma, inoculation routes |
Ayaka Hara, et al. |
2021 |
CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy |
CD1d, iNKT cells, glioblastoma |
Sebastian Kollmann, et al. |
2021 |
A STAT5B-CD9 axis determines self-renewal in hematopoietic and leukemic stem cells |
HSCs |
Xueliang Gao, et al. |
2021 |
Nuclear PFKP promotes CXCR4 dependent T cell acute lymphoblastic leukemia infiltration. |
CDX, T cell acute lymphoblastic leukemia (T-ALL), CXCR4 |
Jianshui Zhang, et al. |
2021 |
Humanized bone marrow-liver-thymic mouse (hu-BLT mouse), macroglia, HIV-1, central nervous system (CNS), |
|
Camilla Bjørnbak Holst, et al. |
2021 |
Plasma IL-8 and ICOSLG as prognostic biomarkers in glioblastoma |
glioblastoma, IL-8,ICOS ligand,biomarker, CDX |
Malene Bredahl Hansen, et al. |
2021 |
HER2/ErbB2, CDX, ovarian cancer |
|
Helle Samdal, et al. |
2021 |
PDX, colorectal cancer |
|
Wei Dai, et al. |
2021 |
DDR1, TGF-β, uveal melanoma (UM), CDX, metastasis |
|
Haiqing Ni, et al. |
2021 |
Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody |
CD47, CD20, VEGF-A, mAbs, acute myeloid leukemia (AML), PBMCs, humanized |
Haiping Jiang, et al. |
2021 |
PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity |
PD-L1, LAG-3, bsAbs, melanoma, PBMCs, humanized, cancer immunotherapy |
Qingming Wang, et al. |
2021 |
chimeric antigen receptor (CAR), B-cell maturation antigen (BCMA), adoptive T-cell therapy (ACT), truncated human EGFR (eEGFR), multiple myeloma (MM), CDX |
|
Yongliang Liu, et al. |
2021 |
acute myeloid leukemia (AML), CD9, PDX, humanized |
|
Yosuke Nagesawa, et al. |
2021 |
autoimmune, Epstein-Barr virus, HSCs, humanized |
|
Saori Igura, et al. |
2020 |
sarcoplasmic reticulum, skeletal muscle, tubular aggregate |
|
Paul Savage, et al. |
2020 |
PDX, breast cancer |
|
Elly L van der Veen, et al. |
2020 |
Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs. |
melanoma, PD-1, mAb, CDX, HSCs, humanized |
Wanlu Cao, et al. |
2020 |
LGR5 marks targetable tumor-initiating cells in mouse liver cancer |
LGR5, liver cancer, allograft tumor model |
Mari I. Suominen, et al. |
2020 |
prostate cancer bone metastasis, anti-PD-1, HSCs, humanized |
|
Zhihui Kuang, et al. |
2020 |
A Novel Bispecific Antibody with PD-L1-assisted OX40 Activation for Cancer Treatment |
PD-L1, OX40, CD134, bsAbs, PBMC, colon cancer, lung cancer, humanized |
Linlin Ma, et al. |
2020 |
CD47/SIRPα, CD20, CD47, bsAbs, lymphoma |
|
Yan Wang, et al. |
2020 |
CD47, PD-L1, bsAbs, SIRPα |
|
Run Lin, et al. |
2020 |
Fatty Acid Oxidation Controls CD8+ Tissue-Resident Memory T-cell Survival in Gastric Adenocarcinoma |
PD-L1, gastric adenocarcinoma, tissue-resident memory T cells (Trm), PDX, humanized |
Kun Zhang, et al. |
2020 |
CD147, safety, toxicology, RBC, Plasmodium falciparum, humanized |
|
Stijn JH Waaijer, et al. |
2020 |
CD3, glypican 3(GPC3), bsAbs, hepatocellular carcinoma, ovarian clear cell carcinoma, HSCs, humanized |
|
Angelique Sao-Mai Sy Do, et al. |
2020 |
dendritic cell vaccine, CD133, glioblastoma, HSCs, humanized |
|
Shinya Rai, et al. |
2020 |
acute myeloid leukemia (AML), PDX |
|
Jennifer Y.Ge, et al. |
2020 |
Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer |
triple-negative breast cancer (TNBC), CDK4/6 inhibitor, BET inhibitor, CDX |
Ping He, et al. |
2020 |
Co-expressing LRP6 With Anti-CD19 CAR-T Cells for Improved Therapeutic Effect Against B-ALL |
CAR-T cells, T memory cell, B-cell ALL |
Elin M. V. Forsberg, et al. |
2019 |
melanoma,HER2, CAR-T, ACT, |
|
Walid Warda, et al. |
2019 |
chronic myeloid leukemia (CML), IL1RAP, CAR-T, HSCs, humanized |
|
Xiaofang Guo, et al. |
2019 |
CD133+ stem cell, hematopoietic differenciation, humanized |
|
Jie Wang, et al. |
2019 |
Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit |
PD-1,PBMC, receptor occupancy, humanized |
Jing Zhang, et al. |
2019 |
cyclin-dependent kinase 7/9 (CDK7/9) inhibitor, uveal melanoma (UM), CDX, metastasis |
|
Cedric Darini, et al. |
2019 |
An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy |
HER2, PKR, gastric cancer, PDX |
Thi Bui, et al. |
2018 |
immune check point therapy, PD-1, CTLA-4, breast cancer, HSCs, humanized |
|
Berglind O.Einasdottir, et al. |
2018 |
metastatic melanoma, PDX, T cell |
|
Tiina E. Kähkönen, et al. |
2018 |
Cancer-Induced Osteoblastic Bone Growth in a Humanized Mouse Model without Affecting Normal Bone |
breast cancer, HSCs, humanized |
Sarah L. Buchan, et al. |
2018 |
4-1BB, treg cell, PD-1, combined therapy, PBMCs, humanized |
|
Weiling He, et al. |
2017 |
PBMCs, humanized, gastric cancer, CD155T/TIGIT, anti-PD-1 mAbs |
|
Qing Zhang, et al. |
2017 |
chimeric antigen receptor (CAR), T cell, lung cancer, melanoma |
|
Masahiko Yasuda, et al. |
2017 |
Incidence of spontaneous lymphomas in non-experimental NOD/Shi-scid, IL-2Rγ null (NOG) mice |
thymic lymphoma, spontaneous |
R.Ito, et al. |
2016 |
GvHD, CD4+T cell, CD8+T cell, Th17 |
|
B.C.Martel, et al. |
2015 |
Human Atopic Dermatitis Skin-derived T Cells can Induce a Reaction in Mouse Keratinocytes in vivo |
atopic dermatitis (AD), skin-infiltrating T cells, keratinocytes |
A Kitadate, et al. |
2015 |
primary cutaneous T-cell lymphoma (CTCL), non-Hodgkin T/NK-cell lymphoma, CDX |
|
Zhu A Wang, et al. |
2014 |
Luminal cells are favored as the cell of origin for prostate cancer. |
prostate cancer, luminal cell, basal cell, CDX, |
Nicholas Veomatt, et al. |
2014 |
Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein |
leukemia,CDX, mAbs |
Hirotomo Nakata, et al. |
2005 |
HIV,PBMCs |
|
Mamoru Ito, et al. |
2002 |
NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. |
HSCs, humanized |
Yuki Saito, et al. |
2002 |
The in vivo development of human T cells from CD34(+) cells in the murine thymic environment. |
HSCs, humanized |
Takashi Yahata, et al. |
2002 |
HSCs, humanized |
|
|
2002 |
Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/gammacnull mice model |
|